What’s new with MERCURY?

Our latest release: MERCURY™ v3.0

We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.

MERCURY v3.0 has (…)  » 

IntegraGen Achieves CE Mark for Its MERCURY™ Cloud-based Software Tool Which Supports Molecular Tumor Profiling for Cancer Patients

IntegraGen announces the company’s MERCURY cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…)  » 

IntegraGen Update – Still open to meet your research needs

IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.

We have undertaken (…)  » 

COVID-19 update: IntegraGen remains committed to meeting our customers needs

Dear IntegraGen partner and customer,

We value your well-being and understand that the entire community is impacted by the novel coronavirus (COVID-19) outbreak. This is why we are committed to providing consistent and timely support so your important work is not interrupted.

IntegraGen is closely monitoring guidance from health authorities (…)  » 

IntegraGen nominated for a 2018 PrixGalien MedStartup Award

IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…)  » 

IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.

GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…)  » 

GoPath Labs Announces North American Launch of miR-31-3p expression test

GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with (…)  » 

IntegraGen to attend ASCO 2018 – June 1st to 5th in Chicago

IntegraGen will be in attendance at 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1st to June 5th.  The Annual ASCO Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new (…)  » 

Technical Validation Data for miR-31-3p test Published in Biomarker Insights

IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.

The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…)  »